The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: Rapid insulin stimulation by nateglinide in IGT subjects

Endocrine Journal

Volumn 49, Issue 6, 2002, Pages 649-652

  Hirose, Takahisa ^a   Mizuno, Ryuzo ^a   Yoshimoto, Takahiko ^a  

^a Nishinomiya Municipal Central Hospital   (Japan)

Author keywords

Early prandial insulin secretion; Impaired glucose tolerance; Nateglinide; Type 2 diabetes

Indexed keywords

NATEGLINIDE;

ADULT; AGED; ARTICLE; CELL FUNCTION; CELL LOSS; CLINICAL ARTICLE; DIETARY INTAKE; DRUG EFFECT; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESPONSE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL;

AREA UNDER CURVE; BLOOD GLUCOSE; CYCLOHEXANES; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PHENYLALANINE; POSTPRANDIAL PERIOD; PREDIABETIC STATE;

EID: 0036960166     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.49.649     Document Type: Article

References (17)

1. Reaven GM (1998) Banting lecture 1998: role of insulin resistance in human disease. Diabetes 37: 1595-1607.
2. Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J, Gerich J (1992) Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326: 22-29.
3. Weyer C, Bogardus C, Mott DM, Pratley RE (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabtes mellitus. J Clin Invest 104: 787-794.
4. Dunning BE (1997) New non-sulfonylurea insulin secretagogues. Exp Opin Invest Drugs 6: 1041-1048.
5. Kikuchi M (1996) Modulation of insulin secretion in non-insulin dependent diabetes mellitus by two novel oral hypoglycernic agents. NN62 and A-4166. Diabet Med 13, S151-S155.
6. Ikenoue T, Okazaki K, Fujitani S, Tsuchiya Y, Akiyoshi M, Maki T (1997) Effect of a new hypoglycemic agent, A4166 [(-)-N-(trans-4-isoplopylcyclohexyl)-carbonyl]-D-phenylalanine, on postprandial blood glucose excursion: comparison with voglibose and glibenclamide. Biol Pharm Bull 20: 354-359.
7. Hanefeld M, Bouter KP, Dickinson S, Guitard CH (2000) Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 23: 202-207.
8. Dornhorst A (2001) Insulinotropic meglitinide analogues. Lancet 359: 1709-1716.
9. Hollander PA, Zheng H, Schwaretz SL, Foley JE, Gatlin MR, Dunning BE, Haas SJ (2001) Importance of early insulin secretion. Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 24: 983-988.
10. Avignon A, Radauceanu A, Monnier L (1997) Nonfasting plasma glucose is a better marker of diabetic control in type 2 diabetes. Diabetes Care 20: 1822-1826.
11. The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354: 617-621.
12. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A (1999) Impaired glucose tolerance is a risk factor for cardiovascular disease but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes care 22: 920-924.
13. Uchino H, Niwa M, Shimizu T, Nishiyama K, Kawamori R (2000) Impairment of early insulin response after glucose load rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue. Endocr J 47: 639-641.
14. Kalbag JB, Nedelman JR, Walter YH, McLeod JF (2001) Mealtime glucose regulation with nateglinide in healthy volunteers. Diabetes Care 24: 73-77.
15. Laghmich A, Ladriere L, Malaisse-Lagae F, Malaisse WJ (1998) Pancreatic islet responsiveness to D-glucose after repeated administration of repaglinide. Eur J Pharmacol 348: 265-270.
16. Leghmich A, Ladriere L, Malaisse-Lagae F, Malaisse WJ (1999) Long-term effects of glibenclamide and nateglinide upon pancreatic islet function in normal and diabetic rats. Phamacol Res 40: 475-482.
17. Anon. (2001) Navigator; largest diabetes trial announced. Br J Cardiol 8: 550.